Recommendation to Subject Certain Medicines Used in the Treatment of COVID-19 Under Maximum Retail Price
October 25, 2021
RECOMMENDATION TO SUBJECT CERTAIN MEDICINES USED IN THE
TREATMENT OF COVID-19 UNDER MAXIMUM RETAIL PRICE
On 10 September 2021, Proclamation No. 1218 extended the State of Calamity throughout the country until 12 September 2022 due to the Coronavirus-19 (COVID-19) disease. The Department of Health (DOH) continuously monitors the availability and affordability of COVID-19 related health commodities including drugs and medicines.
Numerous reports from consumers have been received by the Department on overpricing of COVID-19 medicines. The DOH, through the Drug Price Advisory Council (DPAC), conducted a price review with an objective of recognizing inefficiencies in the market and identifying measures which shall effectively protect consumers from unfair pricing practices.
After careful analysis of the supply, demand, costs and prevailing prices of COVID-19 medicines, the DPAC recommended to subject the following medicines under price regulation:
Comments, inputs and/or appeals to the recommendation may be submitted to the MRP secretariat through electronic mail at email@example.com. The deadline for submission is on 09 November 2021. Should you wish for an individual company meeting, kindly register through https://bit.ly/MRPcovidmeds on or before 02 November 2021.
Telephone Number: 02-8757734 Loc. 253
Address: 4th Floor, Philippine Blood Center, Lung Center Compound, Quezon Avenue, Quezon City
Email Address: firstname.lastname@example.org